Abstract:Rapamycin is an immunosuppressant that has been shown to prevent tumor growth following organ transplantation. However, its exact mode of antitumor action remains unknown. The present study used the B16‐F10 (B16) murine melanoma model to explore the antitumor mechanism of rapamycin, and it was revealed that rapamycin reduced B16 cell viability in vitro and in vivo . In addition, in vitro and in vivo , the results of western blotting showed that rapamycin reduced Bcl2 expression, and enhanced the protein expression levels of cleaved caspase 3 and Bax, indicating that it can induce the apoptosis of B16 melanoma cells. Furthermore, the results of cell cycle analysis and western blotting showed that rapamycin induced B16 cell cycle arrest in the G 1 phase, based on the reduction in the protein expression levels of CDK1, cyclin D1 and CDK4, as well as the increase in the percentage of cells in G 1 phase. Rapamycin also significantly increased the number of autophagosomes in B16 melanoma cells, as determined by transmission electron microscopy. Furthermore, the results of RT‐qPCR and western blotting showed that rapamycin upregulated the protein expression levels of microtubule‐associated protein light chain 3 (LC3) and Beclin‐1, while downregulating the expression of p62 in vitro and in vivo , thus indicating that rapamycin could trigger cellular autophagy. The present study revealed that rapamycin in combination with chloroquine (CQ) further increased LC3 expression compared with that in the CQ group, suggesting that rapamycin induced an increase in autophagy in B16 cells. Furthermore, the results of western blotting showed that rapamycin blocked the phosphorylation of p70 ribosomal S6 kinase (p70‐S6k) and mammalian target of rapamycin (mTOR) proteins in vitro and in vivo , thus suggesting that rapamycin may exert its antitumor effect by inhibiting the phosphorylation of the mTOR/p70‐S6k pathway. In conclusion, rapamycin may inhibit tumor growth by inducing cellular G1 phase arrest and apoptosis. In addition, rapamycin may exert its antitumor effects by inducing the autophagy of B16 melanoma cells in vitro and in vivo , and the mTOR/p70‐S6k signaling pathway may be involved in this process.

Effects of Rapamycin on mTOR Signaling Pathway in Human Pancreatic Cancer Cell Line SW1990

Rapamycin Inhibits the Proliferation of SW1990 Pancreatic Cancer Cell.

Effects of Rapamycin on Cell Growth and Apoptosis of Pancreatic Carcinoma SW1990 Cells

Rapamycin Reduces Podocyte Apoptosis and is Involved in Autophagy and Mtor/ P70S6K/4EBP1 Signaling.

Antitumor Effects of Rapamycin in Pancreatic Cancer Cells by Inducing Apoptosis and Autophagy.

Effects of rapamycin on number and activity of endothelial progenitor cells

Effects of Rapamycin in Suppressing Proliferation and Inducing Apoptosis of Pancreatic Cancer PC-2 Cells

MicroRNA-21 mediates the rapamycin-induced suppression of endothelial proliferation and migration.

Effects of rapamycin on human hepatocellular carcinoma xenografts in nude mice

Effects of Rapamycin on Growth and Proliferation of Human Non-Small Cell Lung Cancer Cell Line A549

Rapamycin inhibits tumor growth and induces apoptosis in human neuroblastoma cells

Rapamycin prevents early steps of the development of diabetic nephropathy in rats.

[Synergistic Effect of Rapamycin (RPM) and PD98059 on Cell Cycle and Mtor Signal Transduction in Human Colorectal Cancer Cells].

Rapamycin Induces Phenotypic Alterations in Oral Cancer Cells That May Facilitate Antitumor T Cell Responses

Antiproliferative and Overadditive Effects of Rapamycin and FTY720 in Pancreatic Cancer Cells in Vitro

Rapamycin enhances the anti-tumor effect of gemcitabine in pancreatic cancer cells

Rapamycin Inhibiting Jurkat T Cells Viability Through Changing Mrna Expression of Serine/Threonine Protein Phosphatase 2A

Rapamycin Inhibits Epithelial-to-mesenchymal Transition of Peritoneal Mesothelium Cells Through Regulation of Rho GTPases.

[Effects of Rapamycin on angiogenesis and tumor progression in human hepatocellular carcinoma implantation mice].

Rapamycin inhibits B16 melanoma cell viability in vitro and in vivo by inducing autophagy and inhibiting the mTOR/p70‐S6k pathway

Antiproliferative Effect of Rapamycin on Human T-cell Leukemia Cell Line Jurkat by Cell Cycle Arrest and Telomerase Inhibition